Bioline RX (BLRX) & Aptose Biosciences (APTO) Head to Head Contrast

Bioline RX (NASDAQ: BLRX) and Aptose Biosciences (NASDAQ:APTO) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, risk, valuation, dividends, institutional ownership, profitability and analyst recommendations.

Earnings & Valuation

This table compares Bioline RX and Aptose Biosciences’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Bioline RX N/A N/A -$15.84 million ($0.33) -2.97
Aptose Biosciences N/A N/A -$14.06 million ($0.60) -4.73

Aptose Biosciences is trading at a lower price-to-earnings ratio than Bioline RX, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and target prices for Bioline RX and Aptose Biosciences, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bioline RX 0 0 5 0 3.00
Aptose Biosciences 0 1 3 0 2.75

Bioline RX presently has a consensus price target of $3.20, indicating a potential upside of 226.53%. Aptose Biosciences has a consensus price target of $6.00, indicating a potential upside of 111.27%. Given Bioline RX’s stronger consensus rating and higher probable upside, equities analysts plainly believe Bioline RX is more favorable than Aptose Biosciences.

Institutional & Insider Ownership

36.4% of Bioline RX shares are owned by institutional investors. Comparatively, 0.9% of Aptose Biosciences shares are owned by institutional investors. 1.1% of Bioline RX shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares Bioline RX and Aptose Biosciences’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Bioline RX N/A -47.20% -42.23%
Aptose Biosciences N/A -129.12% -111.84%

Risk & Volatility

Bioline RX has a beta of 0.09, indicating that its share price is 91% less volatile than the S&P 500. Comparatively, Aptose Biosciences has a beta of 2.52, indicating that its share price is 152% more volatile than the S&P 500.

Summary

Bioline RX beats Aptose Biosciences on 8 of the 10 factors compared between the two stocks.

About Bioline RX

BioLine RX Ltd is an Israel-based company engaged in the development of therapeutics, from preclinical-stage development to advanced clinical trials, for a range of medical needs. Its clinical therapeutic candidates under development consist of BL-1020 that is in Phase II/III clinical trials to improve cognitive function in schizophrenia patients; BL-1040, which is under pivotal CE-Mark registration trial for the prevention of cardiac remodeling following an acute myocardial infarction; BL-5010, which has completed Phase I/II clinical trials for non-surgical removal of skin lesions; BL-1021 that has completed Phase Ia clinical trial for the treatment of neuropathic pain or pain that results from damage to nerve fibers, and BL-7040, a synthetic oligonucleotide, which is in Phase II clinical trial for the treatment of inflammatory bowel disease. The Company also has 11 pre-clinical stage development products for various indications.

About Aptose Biosciences

Aptose Biosciences Inc. (Aptose) is a clinical-stage biotechnology company. The Company is engaged in the development of anticancer drugs that target specific epigenetic processes and signal transduction abnormalities that underlie a particular life-threatening malignancy. Its product pipeline includes cancer drug candidates that exert activity as stand-alone agents and that enhance the activities of other anticancer agents without causing overlapping toxicities. The Company develops therapeutics focused on epigenetic processes and signal transduction abnormalities at the edge of cancer research, coupled with companion diagnostics to identify the optimal patient population for its products. The Company’s APTO-253 is a small molecule that can induce expression of the genes that codes for the Kruppel-like factor 4 (KLF4) master transcription factor and the p21 cell cycle inhibitor protein.

Receive News & Ratings for Bioline RX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioline RX and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply